Assessing the Added Value of Fixed-Dose Combinations in Non-Communicable Diseases

This cross-country HTA analysis investigates how fixed-dose combinations (FDCs) targeting non-communicable diseases (NCDs) have been evaluated for reimbursement in Canada, Scotland, France, and Germany over the past decade. Despite potential benefits in adherence and quality of life, FDCs face inconsistent appraisal due to differing interpretations of clinical and economic evidence.

The study reveals that HTA outcomes were more favorable for asthma-related FDCs and those demonstrating cost savings or improved disease control. However, patient-centric benefits like reduced pill burden are rarely accepted as formal endpoints. Presented at ISPOR 2025 in Montreal, these findings highlight the challenges and opportunities in demonstrating value for FDCs within fragmented HTA frameworks.

Please click here to download the poster
‍‍
Don’t forget to subscribe to our newsletter below for the latest company updates, recently published HTA guidance, industry insights, and more!

‍

‍

‍